

Performance in Initiating Clinical Trials Q2 2017-2018  
70 day benchmark - first participant recruited within 70 days

Ethics Committee Number	IRAS Number	Name of Trial	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site confirmed by Sponsor	Date Site confirmed	Date Site Ready to Start	Date of First Patient Recruited	Target Met	Source of Delay	Comments
16/ee/0318	201898	A randomised pragmatic trial comparing the clinical and cost effectiveness of lithium and quetiapine augmentation in <del>treatment resistant depression</del>	28/04/2016	17/01/2017	20/10/2016	17/01/2017	17/01/2017	24/01/2017	21/03/2017	Yes		
16/lo/1086	203002	A Double-Blind, Placebo-Controlled, Multicenter Study of Sirukumab as Adjunctive Treatment to a MonoAminergic antidepressant in Adults with Major Depressive Disorder	12/05/2016	06/02/2017	11/08/2016	31/01/2017	07/02/2017	17/02/2017		No	Neither sponsor or NHS provider	Study is extremely difficult to recruit to nationally.GP PIC screening initiated locally
16/sc/0363	205067	RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTI-CENTER REGISTRATION TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF TTP488 IN PATIENTS WITH MILD ALZHEIMER'S DISEASE RECEIVING ACETYLCHOLINESTERASE INHIBITORS AND/OR MEMANTINE (STEADFAST)	17/06/2016	20/10/2016	04/10/2016	21/10/2016	24/10/2016	24/10/2016	20/12/2016	Yes		
16/sc/0618	215934	Finding out whether virtual reality may help individuals feel safer: a pilot study	18/11/2016	20/12/2016	13/12/2016	21/12/2016	21/12/2016	21/12/2016	31/07/2017	no	Sponsor	Problems with the virtual reality programm resulted on delays to recruitment
16/ss/0115	206867	A Parallel-Group, Double-Blind, Long Term Safety and Efficacy Trial of MK-8931 (SCH 900931) in Subjects with Amnestic Mild Cognitive Impairment Due to Alzheimer's Disease	20/09/2016	06/02/2017	25/07/2016	12/12/2016	12/12/2016	06/02/2017	06/03/2017	Yes		

Performance in Initiating Clinical Trials Q2 2017-2018  
70 day benchmark - first participant recruited within 70 days

Ethics Committee Number	IRAS Number	Name of Trial	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site confirmed by Sponsor	Date Site confirmed	Date Site Ready to Start	Date of First Patient Recruited	Target Met	Source of Delay	Comments
16/lo/1862	206680	The SlowMo Trial: A randomised controlled trial to evaluate the outcomes and mechanisms of a novel digital intervention for persecutory delusion	08/12/2016	26/03/2017	01/11/2016	06/04/2017	07/04/2017	07/04/2017	16/05/2017	Yes		
16/SC/0654	214951	Effects of Modulating the Immune System with Prebiotics on Cognition and Weight in Patients with Psychosis	07/12/2016	06/04/2017	07/02/2017	06/04/2017	07/04/2017	07/04/2017	17/05/2017	Yes		
15/EM/0510	209020	A RANDOMISED CONTROLLED TRIAL OF ANTIPSYCHOTIC MEDICATION IN COMPARISON TO PSYCHOLOGICAL INTERVENTION AND A COMBINED TREATMENT IN CHILDREN AND YOUNG PEOPLE WITH FIRST EPISODE PSYCHOSIS: A FEASIBILITY STUDY	22/03/2017	04/05/2017	09/02/2017	04/05/2017	05/05/2017	05/05/2017	01/06/2017	Yes		
16/LO/1820	212826	Randomised, double-blind, placebo controlled trial evaluating the effects of naloxone hydrochloride nasal spray on eating behaviours in bulimia nervosa (OPIANT)	17/06/2016	23/05/2017	29/09/2016	19/05/2017	23/05/2017	23/05/2017		No	NHS and Sponsor	Study stopped following discussions between site and sponsor due to unforeseen circumstances regarding staff shortages in very small department
17/SC/0068	215219	Non-contact infrared thermometers for measuring body temperature in acutely ill children: a method comparison study (METRIC)	24/01/2017	23/05/2017	17/03/2017	08/05/2017	23/05/2017	23/05/2017	09/06/2017	Yes		

Performance in Initiating Clinical Trials Q2 2017-2018  
70 day benchmark - first participant recruited within 70 days

Ethics Committee Number	IRAS Number	Name of Trial	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site confirmed by Sponsor	Date Site confirmed	Date Site Ready to Start	Date of First Patient Recruited	Target Met	Source of Delay	Comments
16/SC/0435	212314	54135419TRD3008 An Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression Safety and Sustenance of Esketamine Treatment Response With Repeated Doses at Intervals Determined by Symptom Severity (SUSTAIN-3)	07/07/2016	20/06/2017	14/03/2017	21/06/2017	27/06/2017	19/07/2017	11/08/2017	Yes		
16/LO/1377	197114	A multicentre randomised controlled trial to examine whether the addition of a patient and carer skills-sharing intervention improves long-term patient wellbeing following hospital treatment for anorexia nervosa (TRIANGLE)	22/11/2016	30/06/2017	26/10/2016	30/06/2017	03/07/2017	03/07/2017	16/08/2017	Yes		
17/WA/0085	219483	TACKling chronic depression - adapting and testing a technology supported patient-centred and solution-focused intervention (DIALOG+) for people with chronic depression (TACK)	24/07/2017	06/09/2017	31/03/2017	12/07/2017	08/09/2017	08/09/2017		Within 70 Days		
17/WM/0146	220303	A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects with Early Alzheimer's Disease; DEME 32112 (EISAI E2609)	05/04/2017	26/09/2017	21/08/2017	25/09/2017	26/09/2017	26/09/2017		Within 70 Days		